CHEMOTHERAPEUTIC EFFICACY OF A NEWLY SYNTHESIZED BENZOXAZINORIFAMYCIN, KRM-1648, AGAINST MYCOBACTERIUM-AVIUM COMPLEX INFECTION INDUCED IN MICE

被引:51
作者
TOMIOKA, H [1 ]
SAITO, H [1 ]
SATO, K [1 ]
YAMANE, T [1 ]
YAMASHITA, K [1 ]
HOSOE, K [1 ]
FUJII, K [1 ]
HIDAKA, T [1 ]
机构
[1] KANEKA CORP,BIOCHEM RES LABS,TAKASAGO 676,JAPAN
关键词
D O I
10.1128/AAC.36.2.387
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Newly synthesized benzoxazinorifamycin, KRM-1648, was studied for its in vivo anti-Mycobacterium avium complex (MAC) activities. When the MICs were determined by the agar dilution method with Middlebrook 7H11 agar medium, KRM-1648 exhibited similarly potent in vitro antimicrobial activities against the MAC isolated from AIDS and non-AIDS patients, indicating possible usefulness of KRM-1648 against AIDS-associated MAC infections. KRM-1648 exhibited potent therapeutic activity against experimental murine infections induced by M. intracellulare N-260 (virulent strain) and N-478, which has much weaker virulence. Similarly, KRM-1648 exhibited an excellent therapeutic efficacy against M. intracellulare infection induced in NK-cell-deficient beige mice (as a plausible model for AIDS-associated MAC infection), in which a much more progressed state of gross lesions and bacterial loads at the sites of infection were observed. When the infected beige mice were killed at weeks 4 and 8, obvious therapeutic efficacy was seen on the basis of reduction in the incidence and degree of lung lesions and bacterial loads in the lungs and spleen with infections due to M. intracellulare N-241, N-256, and N-260. In this case, the efficacy was the highest in N-260 infection, followed by strain N-241. When mice were observed until infection-induced death, survival time of the infected beige mice was found to be prolonged by KRM treatment. However, KRM-1648 was not efficacious in suppressing the progression of pulmonary lesions and the increase in bacterial loads at the sites of infection, including lungs and spleen, at the late phase of infection. This may imply some difficulty with chemotherapy for AIDS-associated MAC infection, even with KRM-1648 treatment, which has excellent in vitro and in vivo anti-MAC activities, as shown in the present study.
引用
收藏
页码:387 / 393
页数:7
相关论文
共 39 条
[1]   ANTI-BACTERIAL ACTIVITY OF DL-473, A NEW SEMI-SYNTHETIC RIFAMYCIN DERIVATIVE [J].
ARIOLI, V ;
BERTI, M ;
CARNITI, G ;
RANDISI, E ;
ROSSI, E ;
SCOTTI, R .
JOURNAL OF ANTIBIOTICS, 1981, 34 (08) :1026-1032
[2]  
BACA ME, 1989, IMMUNOLOGY, V66, P131
[3]  
BRUNA CD, 1983, J ANTIBIOT, V36, P1502
[4]   TREATMENT OF DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN AIDS WITH AMIKACIN, ETHAMBUTOL, RIFAMPIN, AND CIPROFLOXACIN [J].
CHIU, J ;
NUSSBAUM, J ;
BOZZETTE, S ;
TILLES, JG ;
YOUNG, LS ;
LEEDOM, J ;
HESELTINE, PNR ;
MCCUTCHAN, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (05) :358-361
[5]   COMPARATIVE INVITRO ACTIVITIES OF MDL 473, RIFAMPIN, AND ANSAMYCIN AGAINST MYCOBACTERIUM-INTRACELLULARE [J].
CYNAMON, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (03) :440-441
[6]  
DAVIDSON PT, 1981, REV INFECT DIS, V3, P1052
[7]   INVITRO ACTIVITIES AGAINST MYCOBACTERIA OF 2 LONG-ACTING RIFAMYCINS, FCE22807 AND CGP40/469A (SPA-S-565) [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1990, 71 (02) :109-115
[8]   AN ACUTE INFECTION MODEL FOR MYCOBACTERIUM-INTRACELLULARE DISEASE USING BEIGE MICE - PRELIMINARY-RESULTS [J].
GANGADHARAM, PR ;
EDWARDS, CK ;
MURTHY, PS ;
PRATT, PF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 127 (05) :648-649
[9]   THE BEIGE MOUSE MODEL FOR MYCOBACTERIUM-AVIUM COMPLEX (MAC) DISEASE - OPTIMAL CONDITIONS FOR THE HOST AND PARASITE [J].
GANGADHARAM, PRJ ;
PERUMAL, VK ;
FARHI, DC ;
LABRECQUE, J .
TUBERCLE, 1989, 70 (04) :257-271
[10]   ANTIBACTERIAL ACTIVITY OF HUMAN NATURAL-KILLER CELLS [J].
GARCIAPENARRUBIA, P ;
KOSTER, FT ;
KELLEY, RO ;
MCDOWELL, TD ;
BANKHURST, AD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (01) :99-113